

**RECEIVED
CENTRAL FAX CENTER****MAR 13 2006****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**In the Application of:
TSAI, DavidExaminer: Padmashri Ponnaluri
Art Unit: 1639Serial No. 11/315,810

Attorney Docket No.: 04-01-2174

Filed: 12/22/2005

Title: A method for treating obesity
with Zinc-charged polypeptidesCertificate of Transmission (37 CFR 1.8):

I hereby certify that this correspondence is being transmitted to the United States Patent and Trademark Office by facsimile (571) 273-8300 (ten pages) on March 13, 2006.

By: R. Joseph Trojan
Reg. No. 34,264**AMENDMENT AND RESPONSE
TO FINAL OFFICE ACTION DATED 02/02/2006**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**TELEPHONE INTERVIEW SUMMARY**

Dear Sir or Madam:

On February 27, 2006 at 11:50 PST the Applicant initiated a telephone interview regarding this application with Examiner Padmashri Ponnaluri. Per Examiner's request, the Applicant hereby memorializes the content of the interview.

An agreement has been reached between the Examiner and the Applicant regarding the amendments to the single pending claim that would place the application in condition for allowance. Specifically, the Examiner recommended and the Applicant agreed to amend the single pending claim (Claim 15) as follows:

"A fetuin polypeptide ~~comprising an~~ consisting of the amino acid sequence of His-Ser-Phe-Ser-Gly-Val-Ala-Ser-Val-Glu SEQ. ID NO: 4,

Application Number 10/772,537
Art Unit 1639

wherein said polypeptide causes apoptosis in colon and prostate cancer cells”

The examiner also noted that such a use of sequence identifier would address the Claim Objections of the February 2, 2006 Office Action.